Handling punctate keratitis resulting from systemic cytarabine.
A young patient with acute myelogenous leukemia was treated with high-dose cytarabine (3.0 g/m2 every 12 hours). After five days of treatment, he developed severe photophobia and decreased visual acuity. On examination, progressive punctate keratitis was found. We discuss the mechanism of the cytarabine-induced corneal toxicity and the prophylactic use of topical corticosteroids.
Friedland
S
S
Department of Ophthalmology, Beilinson Medical Center, Petah Tiqva, Israel.
Loya
N
N
Shapiro
A
A
D000328:Adult; D002701:Chloramphenicol / Q000627:therapeutic use; D003318:Corneal Opacity / Q000139:chemically induced; D003561:Cytarabine / Q000009:adverse effects* / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007634:Keratitis / Q000139:chemically induced* / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008297:Male; D009824:Ointments; D011292:Premedication; D014792:Visual Acuity
D005938:Glucocorticoids; D009824:Ointments; D003561:Cytarabine; D002701:Chloramphenicol